Annual Report 2021
Part II: Corporate Governance
40
individual member of the investment committee, or any other individual at MVM Partners LLP, has the power to unilaterally make
investment decisions for the MVM Entities or to direct the voting or disposition of the shares; (iv) Dr. Eric Bednarski, an investment
manager and partner at MVM Partners LLP, is a member of the board of directors of the Company; and (v) the MVM Entities
entered into a joint filing agreement, dated 27 December 2021, a copy of which is attached to the statement on Schedule 13D.
(4)
Bleichroeder LP and Bleichroeder Holdings LLC jointly (collectively, the "Bleichroeder Entities") filed with the SEC a statement
on Schedule 13G according to which the aggregate number of shares beneficially owned by the Bleichroeder Entities represents
15.25% of the outstanding shares and voting rights of the Company at the time of statement on Schedule 13G. Notably, it follows
from the statement on Schedule 13D that Bleichroeder LP, an investment adviser registered under Section 203 of the Investment
Advisers Act of 1940, is deemed to be the beneficial owner of 23,783,330 shares, or 15.25%, of the common stock believed to be
outstanding. The 23,783,330 shares include 4,200,000 shares of common stock and 19,583,330 shares of common stock underlying
ADSs. 21 April Fund Ltd., a Cayman Islands company for which Bleichroeder LP acts as investment adviser, holds 15,042,162
of these 23,783,330 shares, which equates to 9.64% of common stock believed to be outstanding. Clients of Bleichroeder have
the right to receive and the ultimate power to direct the receipt of dividends from, or the proceeds of the sale of, such securities.
(5)
Valiance Asset Management Limited ("Valiance Management"), TopMDx Ltd. ("TopMDx"), Valiance Life Sciences Growth
Investments SICAV-SIF ("LSGI Fund") and Valiance Life Sciences Growth Investments GP S.à r.l. ("LSGI GP") (collectively, the
"Valiance Entities") jointly filed with the SEC a statement on Schedule 13D according to which the aggregate number of shares
beneficially owned by the Valiance Entities represents 12.2% of the outstanding shares and voting rights of the Company at the
time of statement on Schedule 13D. Notably, it follows from the statement on Schedule 13D that an aggregate of 19,027,014
ordinary shares are beneficially owned by Valiance Management, which consist of (i) 8,834,387 ordinary shares, and 160,083
ADSs representing 1,600,830 ordinary shares held by TopMDx, an exempted closed-ended fund registered in British Virgin
Islands of which Valiance Asset Management is the investment manager, and (ii) 8,591,797 ordinary shares held by LSGI Fund,
a Luxembourg investment fund of which LSGI GP serves as investment manager. The statement on Schedule 13D also specifies
that (i) Jan Pensaert, the Founding Managing Partner of Valiance Asset Management, which is affiliated with the Valiance Entities,
serves as a member of the Company's board of directors and, in such capacity, may have influence over the corporate activities of
the the Company; and (ii) Valiance Management serves as the investment manager of LSGI GP, which is the investment manager
of LSGI Fund; however, no agreement exists between Valiance Management and LSGI GP for the purposes of acquiring, holding,
voting, or disposing of the equity securities of the the Company and, accordingly, the Valiance Entities disclaim the existence
of, or membership in, a “group” for purposes of the statement on Schedule 13D. The shareholding on a fully diluted basis takes
into account the exercise of 80,000 share options for new shares of the Company, held by Valiance Advisors LLP, a Director of
the Company and a related person to Valiance Asset Management Limited, TopMDx Limited and Valiance Life Sciences Growth
Investments SICAV-SIF.
(6)
Biovest NV and RMM, S.A. (collectively, the "Biovest Entities") jointly filed with the SEC a statement on Schedule 13G according to
which the aggregate number of shares beneficially owned by the Biovest Entities represents 7.1% of the outstanding shares and
voting rights of the Company at the time of statement on Schedule 13G. Notably, it follows from the statement on Schedule 13G
that 11,008,257 ordinary shares held by Biovest NV. The statement on Schedule 13G also specifies that (i) RMM, S.A. is the sole
owner of Biovest NV and pursuant to an understanding with Biovest NV, decisions relating to the voting and dispositive power of
the shares are shared between Biovest NV and the board of director of RMM, S.A. (the "Board"); and (ii) voting and investment
power over the shares managed by the Board is exercised jointly by more than three natural persons and voting and disposition
decisions require the approval of a majority of such persons; accordingly, no single natural person has a controlling decision and
no individual director of RMM, S.A. should be deemed to be a beneficial owner of the shares. The shareholding on a fully diluted
basis does not take into account the exercise of 92,000 share options for new shares of the Company, held by RR-Invest S.à.r.l.,
a Director of the Company and a company controlled by Mr. Rudi Mariën, who is a director of RMM, S.A.
No other shareholders, acting alone or in concert with other shareholders, notified the Company of a participation or
an agreement to act in concert in relation to 3% or more of the current total existing voting rights attached to the voting
securities of the Company.
Each shareholder of the Company is entitled to one vote per share.